Mirvaso in Use Study



Status:Completed
Conditions:Cosmetic
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:12/21/2017
Start Date:September 2014
End Date:August 2015

Use our guide to learn which trials are right for you!

MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)

This study is designed to:

1. assess the signs and symptoms of rosacea, including erythema, without treatment and
during treatment with Mirvaso® gel

2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment

3. gain a better understanding of the real-world use of Mirvaso® on the pattern and
management of facial erythema of rosacea.


Inclusion Criteria:

1. Subjects must be 18 years of age or older at time of study consent.

2. Subjects with a board certified dermatologist (BCD) clinical diagnosis of facial
erythema of rosacea and eligible for treatment with Mirvaso® (brimonidine) topical
gel, 0.33% per package insert.

3. Subjects with a clinician's erythema assessment (CEA) score of ~3 at Screening Visit
1.

4. Subjects with less than 3 facial inflammatory lesions of rosacea at Screening/Visit 1.

5. Subjects must be willing and able to give written informed consent including
photography consent. Consent and photo consent will be obtained prior to any study
related procedures

6. Females of childbearing potential with a negative urine pregnancy test (UPT) at Visit
1 (prior to test article application) or females of non-childbearing potential (deemed
as post-menopausal [absence of menstrual bleeding for at least 1 year prior to
enrollment], hysterectomy or bilateral oophorectomy).

Exclusion Criteria:

1. Subjects with particular forms of rosacea (rosacea conglobata, rosacea fulminans,
isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial
dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis,
facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic
telangiectasia.

2. Subjects with current diagnosis of Raynaud's syndrome, thromboangiitis obliterans,
orthostatic hypotension, severe cardiovascular disease, cerebral or coronary
insufficiency, renal or hepatic impairment, scleroderma, Sjogren's syndrome or
depression.

3. Subjects with previous refractive eye surgery such as photorefractive keratectomy,
laser-assisted sub-epithelial keratectomy, or laser-assisted in situ keratomileusis.

4. Current treatment with monoamine oxidase inhibitors.

5. Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or
alpha- agonists.

6. Less than 3 months (90 days) stable dose treatment with tricyclic antidepressants,
cardiac glycosides, beta blockers or other antihypertensive agents.

7. Subjects with any uncontrolled chronic or serious disease or medical condition that
would normally prevent participation in a clinical study, or, in the judgment of the
investigator, would put the subjects at undue risk, or might confound the study
assessments (e.g., other dermatological diseases), or might interfere with the
subjects' participation in the study, (e.g., planned hospitalization during the
study).

8. Subjects who have received, applied, or taken treatments with drugs, cosmetics or
devices known to cause facial erythema and who are deemed ineligible by the
investigator.

9. Subjects with known allergies or sensitivities to any component of the study drug,
including the active ingredient brimonidine tartrate label (refer to the package
insert for Mirvaso® (brimonidine) topical gel, 0.33%).

10. Subjects with prior treatment with brimonidine gel, oxymetazoline or other (topical
and/or systemic) alpha adrenergic agonists.

11. Subjects who are pregnant or breast-feeding or planning to become pregnant during the
course of the study.

12. Subjects exposed to excessive ultraviolet (UV) radiation within I week prior to
baseline and/or subject was unwilling to refrain from excessive exposure to UV
radiation during the course of the study.

13. Subjects with the presence of a beard or excessive facial hair that would interfere
with the study treatments or study assessments as deemed by the investigator, and
refusal to remove beard or facial hair for duration of the study.

14. Subjects with non-stable dose of current (last 60 days) use of prescription rosacea
medications.

15. Subjects with uncontrolled rosacea associated with inflammatory pustules and papules.

16. Study site staff, relatives of staff members, or other individuals who would have
access to the clinical study protocol.

17. Subjects with participation in any investigational study within 30 days of entry into
this study or concomitantly with this study
We found this trial at
12
sites
Fort Smith, Arkansas 72916
?
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Arlington, Texas 76011
?
mi
from
Arlington, TX
Click here to add this to my saved trials
Hazleton, Pennsylvania 18201
?
mi
from
Hazleton, PA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport Beach, California 92663
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Omaha, Nebraska 68144
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Sacramento, California 95819
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Antonio, Texas 78218
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Santa Rosa, California 95403
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Warren, Michigan 48093
?
mi
from
Warren, MI
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials